Literature DB >> 169107

Evaluation of different antibiotic actions combined with rifampicin. In vitro synergism against Pseudomonas and Proteus.

M T Urena, I Barasoain, M Espinosa, E Garcia, A Portoles.   

Abstract

Associations of penicillin, streptomycin, tetracycline and polymyxin B with rifampicin were tested for synergism against Pseudomonas and Proteus pathological strains. The combination of rifampicin and polymyxin B was clearly synergistic for all strains as it was evaluated by isobolograms and killing curvesmthe bactericidal action of this association, without any cross-resistance between its components, may eradicate gram-negative bacteria infections with marked polyvalent drug resistances.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 169107     DOI: 10.1159/000221850

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  5 in total

1.  In vitro additive effect of polymxin B and rifampin against Serratia marcesen.

Authors:  W H Traub; I Kleber
Journal:  Antimicrob Agents Chemother       Date:  1975-06       Impact factor: 5.191

Review 2.  Polymyxins revisited.

Authors:  David Landman; Claudiu Georgescu; Don Antonio Martin; John Quale
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 3.  Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.

Authors:  Souha S Kanj; Zeina A Kanafani
Journal:  Mayo Clin Proc       Date:  2011-03       Impact factor: 7.616

Review 4.  Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

Authors:  Tiphaine Goulenok; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

5.  Combination of minocycline and rifampicin against methicillin- and gentamicin-resistant Staphylococcus aureus.

Authors:  E Yourassowsky; M P van der Linden; M J Lismont; F Crokaert
Journal:  J Clin Pathol       Date:  1981-05       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.